Form 4: Marchex COO Awarded 300,000 Equity Grants

Marchex's Chief Operating Officer and CLO, Francis J. Feeney, received awards of 150,000 Restricted Stock Units and 150,000 Employee Stock Options, effective October 16, 2025.

Summary

• Francis J. Feeney, Chief Operating Officer & CLO of Marchex Inc. (MCHX), was granted equity awards on October 16, 2025.
• The awards include 150,000 Restricted Stock Units (RSUs) and 150,000 Employee Stock Options.
• Each RSU represents the right to receive one share of the Corporation's Class B Common Stock upon vesting.
• The RSUs vest in full on the fourth anniversary of the grant date, which is October 16, 2029.
• The employee stock options have an exercise price of $1.81 per share.
• The stock options vest 25% on the first anniversary of the grant date (October 16, 2026), with the remainder vesting quarterly over the subsequent three years in equal increments of 6.25% of the aggregate amount.
• The stock options expire on October 16, 2035.
• Following these transactions, Mr. Feeney beneficially owns 150,000 Restricted Stock Units and 150,000 Employee Stock Options.

Sentiment

Score: 7

Explanation: The filing reports a standard executive equity compensation grant, which is a neutral event in itself but positively aligns management's long-term interests with shareholder value. It does not contain any unexpected financial results or strategic announcements.

Positives

• The equity awards align management's interests with long-term shareholder value through multi-year vesting schedules.
• The grant of 300,000 equity instruments (RSUs and options) represents a significant incentive for the Chief Operating Officer & CLO to drive company performance.
• The stock options have an exercise price of $1.81, providing a clear benchmark for future stock price appreciation required for the options to be in-the-money.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders as the RSUs vest and options are exercised.
• The value of the awards is contingent on future stock performance, meaning there is no guaranteed value for the recipient or direct immediate benefit to the company's cash flow.

Risks

• Future stock price performance may not exceed the option exercise price of $1.81, rendering the options worthless.
• The value of the Restricted Stock Units is subject to market fluctuations of Marchex's Class B Common Stock until vesting.
• The company faces the risk of increased share count and potential dilution upon the vesting and exercise of these equity awards.

Future Outlook

The equity awards are designed to incentivize long-term performance, with vesting schedules extending over four years for both Restricted Stock Units and Employee Stock Options. The stock options have a ten-year expiration period, indicating a long-term horizon for potential value realization.

Industry Context

The granting of Restricted Stock Units and stock options is a standard practice in executive compensation across various industries, particularly in technology and growth-oriented companies. This approach aims to align executive incentives with shareholder interests by tying a significant portion of compensation to the company's stock performance over several years.

Comparison to Industry Standards

• The use of a combination of Restricted Stock Units (RSUs) and stock options is a common practice in executive compensation packages, similar to those offered by comparable companies in the software and digital advertising sectors.
• The four-year vesting schedule for both RSUs and stock options is typical for executive equity awards, designed to promote long-term retention and performance alignment, consistent with practices at companies like LiveRamp Holdings, Inc. (RAMP) or VeriSign, Inc. (VRSN) for their executive teams.
• The specific exercise price of $1.81 for the options would be evaluated against Marchex's stock price performance and peer group valuations, though no direct comparison data is available in this filing.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and exercise of the equity awards, but also potential benefit from improved executive performance aligned with stock price appreciation.
• Employees: The equity awards serve as a retention and incentive mechanism for a key executive, potentially fostering a stable leadership environment.

Next Steps

• The Restricted Stock Units will vest in full on October 16, 2029.
• The Employee Stock Options will begin vesting on October 16, 2026, with subsequent quarterly vesting increments.
• The Employee Stock Options will expire on October 16, 2035.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a senior executive. While it aligns management's interests with long-term shareholder value, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure of executive incentive compensation.

Keywords

Marchex, MCHX, Francis J Feeney, Chief Operating Officer, CLO, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Form 4, Executive Compensation, Vesting, Class B Common Stock